This paper reports on the STAR-TREC and TESAR trials, which investigate organ preservation (non-operative management) as an alternative to total mesorectal excision (TME) surgery in rectal cancer patients who achieve a clinical complete or near-complete response to (chemo)radiotherapy.
The full text of the paper was not available for extraction of specific numerical results, response rates, or detailed outcome data; key findings and limitations cannot be confirmed from the provided metadata alone.
Clinicians managing rectal cancer should follow the STAR-TREC and TESAR trial results closely, as they are designed to provide high-level evidence for or against organ preservation strategies as standard-of-care alternatives to TME.
Explore related topics
